Search

Gowsala P Sivam

from Edmonds, WA
Age ~80

Gowsala Sivam Phones & Addresses

  • 922 Hindley Ln, Edmonds, WA 98020 (425) 697-4695 (206) 546-2051
  • 23504 97Th Ave, Edmonds, WA 98020 (206) 546-2051
  • 14500 Juanita Woodinville Way NE, Bothell, WA 98011
  • Kenmore, WA
  • Seattle, WA
  • 922 Hindley Ln, Edmonds, WA 98020

Work

Company: Bastyr university Position: Assoc.professor

Education

Degree: Bachelor's degree or higher

Industries

Higher Education

Resumes

Resumes

Gowsala Sivam Photo 1

Assoc.professor

View page
Location:
Seattle, WA
Industry:
Higher Education
Work:
Bastyr University
Assoc.professor

Publications

Us Patents

Targeting Substance-Diagnostic/Therapeutic Agent Conjugates Having Schiff Base Linkages And Methods For Their Preparation

View page
US Patent:
55212905, May 28, 1996
Filed:
Nov 21, 1994
Appl. No.:
8/342789
Inventors:
Gowsala P. Sivam - Edmonds WA
A. Charles Morgan - Edmonds WA
Vivekananda M. Vrudhula - Edmonds WA
Assignee:
NeoRx Corporation - Seattle WA
International Classification:
C07K 1600
C07K 1646
C07K 1900
US Classification:
5303915
Abstract:
Targeting substance-diagnostic/therapeutic agent conjugates joined by stabilized Schiff base or hydrazone linkages are disclosed. In addition, slow release carrier-drug pharmaceuticals are described. The diagnostic and therapeutic conjugates and pharmaceuticals of the present invention provide certain advantages relating to in vivo administration, including controlled release of the active agent at a target site.

Immunoconjugates Joined By Thioether Bonds Having Reduced Toxicity And Improved Selectivity

View page
US Patent:
49819798, Jan 1, 1991
Filed:
Sep 10, 1987
Appl. No.:
7/095178
Inventors:
Gowsala Sivam - Edmonds WA
Assignee:
NeoRx Corporation - WA
International Classification:
C07D20740
G01N 33536
C07K 100
US Classification:
548545
Abstract:
Method for producing an immunoconjugate comprising the steps of reacting a toxin or protein with a heterobifunctional reagent having the following general formula: ##STR1## where R. sub. 1 is: ##STR2## where n=1 to 10; and where R. sub. 2 is selected from the group consisting of o- and p-nitrophenyl, 2-chloro-4-nitrophenyl, cyanomethyl, 2-mercaptopyridyl, hydroxybenztriazole, N-hydroxysuccinimide, trichlorophenyl, tetrafluorophenyl, 2-fluorophenyl, 4-fluoropheyl, 2,4-difluorophenyl, o-nitro-p-sulfophenyl, N-hydroxyphthalimide, N,N-diethylamino, N-hydroxypyrrolidone, tetrafluorothiophenyl, and 2,3,5,6-tetrafluorophenyl, under reactive conditions, thereby forming a derivatized toxin or protein. The derivatized toxin or protein is separated from the reaction mixture and combined with an antibody or antibody fragment under reactive conditions, such that at least one native disulfide bond is reduced to produce at least one thiol group, capable of forming a thioether bond between said thiol group and the maleimide group of said derivatized toxin, or protein thereby forming an immunoconjugate. The preferred heterobifunctional linking group is succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC).

Alteration Of Pharmacokinetics Of Proteins By Charge Modification

View page
US Patent:
56351801, Jun 3, 1997
Filed:
Sep 26, 1995
Appl. No.:
8/533675
Inventors:
Alton C. Morgan - Edmonds WA
Gowsala P. Sivam - Edmonds WA
Paul G. Abrams - Seattle WA
Assignee:
NeoRx Corporation - Seattle WA
International Classification:
A61K 39395
C07K 1600
US Classification:
4241831
Abstract:
There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic agent at the target site. Conversely, charge-modification to cause a basic shift in the isoelectric point of the conjugate reduces serum half-life upon in vivo use for diagnostic imaging purposes and results in higher target-to-background ratios.

Trichothecene Conjugates

View page
US Patent:
51571048, Oct 20, 1992
Filed:
May 16, 1988
Appl. No.:
7/194642
Inventors:
Gowsala Sivam - Edmonds WA
Paul G. Abrams - Seattle WA
Assignee:
NeoRx Corporation - Seattle WA
International Classification:
C07K 730
US Classification:
530309
Abstract:
Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or fragments thereof that recognize antigens that are present only on tumor cells or are augmented in their expression on tumor cells as compared to normal tissues. Trichothecene molecules are coupled to the agent through non-covalent and covalent linkages, such as peptide bonds, disulfide bonds, thioester bonds, or thioether bonds. A method for inhibiting the growth and metabolism of antigen-positive cells is also disclosed.

Trichothecene Conjugates And Methods Of Use

View page
US Patent:
49064525, Mar 6, 1990
Filed:
Apr 28, 1988
Appl. No.:
7/187113
Inventors:
Gowsala Sivam - Edmonds WA
Assignee:
Neorx Corporation - Seattle WA
International Classification:
A61K 39395
US Classification:
424 10
Abstract:
Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or fragments thereof that recognize antigens that are present only on tumor cells or are augmented in their expression on tumor cells as compared to normal tissues. Trichothecene molecules are coupled to the agent through non-covalent and covalent linkages, such as peptide bonds, disulfide bonds, thioester bonds, or thioether bonds. Methods for reducing intoxification in a recipient of a trichothecene and an agent and for producing a trichothecene conjugate with improved solubility are also disclosed.

Conjugates Having Improved Characteristics For In Vivo Administration

View page
US Patent:
51169444, May 26, 1992
Filed:
Dec 29, 1989
Appl. No.:
7/459068
Inventors:
Gowsala P. Sivam - Edmonds WA
A. Charles Morgan - Edmonds WA
Assignee:
NeoRx Corporation - Seattle WA
International Classification:
C07K 1702
US Classification:
530362
Abstract:
Conjugates comprising a therapeutically effective proteinaceous active moiety linked to an albumin moiety which exhibit enhanced serum half-life and stability properties are disclosed. The conjugates may additionally comprise targeting moieties to facilitate selective localization of the active moiety at a target site. Conjugates of the present invention comprising an albumin moiety additionally exhibit reduced toxicity, yet maintain a high degree of selectivity and potency.

Alteration Of Pharmacokinetics Of Proteins By Charge Modification

View page
US Patent:
53226780, Jun 21, 1994
Filed:
Feb 17, 1988
Appl. No.:
7/157273
Inventors:
Alton C. Morgan - Edmonds WA
Gowsala P. Sivam - Edmonds WA
Paul G. Abrams - Seattle WA
Assignee:
NeoRx Corporation - Seattle WA
International Classification:
A61K 4300
A61K 39395
US Classification:
424 153
Abstract:
There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic agent at the target site. Conversely, charge-modification to cause a basic shift in the isoelectric point of the conjugate reduces serum half-life upon in vivo use for diagnostic imaging purposes and results in higher target-to-background ratios.
Gowsala P Sivam from Edmonds, WA, age ~80 Get Report